Quantity of cytomegalovirus viruria is a major risk factor for cytomegalovirus disease after renal transplantation

Journal of Medical Virology

Volumn 52, Issue 2, 1997, Pages 200-205

  Cope, A V ^a   Sweny, P ^b   Sabin, C ^a   Rees, L ^b   Griffiths, P D ^a   Emery, V C ^a  

^a ROYAL FREE HOSPITAL   (United Kingdom)

^b ROYAL FREE LONDON NHS FOUNDATION TRUST   (United Kingdom)

Author keywords

Glycoprotein b; QCPCR; Quantitation

Indexed keywords

AZATHIOPRINE; CYCLOSPORIN A; METHYLPREDNISOLONE; PREDNISOLONE; VIRUS GLYCOPROTEIN;

ARTICLE; CONTROLLED STUDY; CYTOMEGALOVIRUS; CYTOMEGALOVIRUS INFECTION; DISEASE SEVERITY; FOLLOW UP; HUMAN; KIDNEY TRANSPLANTATION; MAJOR CLINICAL STUDY; PATIENT CARE; QUANTITATIVE ASSAY; RISK ASSESSMENT;

ADOLESCENT; ADULT; CHILD; CHILD, PRESCHOOL; CYTOMEGALOVIRUS INFECTIONS; HUMANS; KIDNEY TRANSPLANTATION; LONGITUDINAL STUDIES; MIDDLE AGED; POSTOPERATIVE COMPLICATIONS; RISK FACTORS; VIRAL LOAD;

CYTOMEGALOVIRUS; HUMAN HERPESVIRUS 5;

EID: 0031009558     PISSN: 01466615     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1096-9071(199706)52:2<200::AID-JMV14>3.0.CO;2-O     Document Type: Article

References (25)

1. Altman DG (1993): "Practical Statistics for Medical Research." New York: Chapman & Hall.
2. Amlot PL, Rawlings E, Fernando ON, Griffin PJ, Heinrich G, Schreier MH, Castaigne JP, Moore R, Sweny P (1995): Prolonged action of chimeric interleukin-2 receptor (CD25) monoclonal antibody use in cadaveric renal transplantation. Transplantation 7:748-756.
3. Balfour HHJ, Chase BA, Stapleton JT, Simmons RL, Fryd DS (1989): A randomized, placebo-controlled trial of oral acyclovir for the prevention of cytomegalovirus disease in recipients of renal allografts. New England Journal of Medicine 320:1381-1387.
4. Betts RF, Freeman RB, Douglas RG Jr, Talley TE (1977): Clinical manifestations of renal allograft derived primary cytomegalovirus infection. American Journal of Disease Child 131:759-763.
5. Cheeseman SH, Rubin RH, Stewart JA, Tolkoff-Rubin NE, Cosimi AB, Cantell K, Gilbert J, Winkle S, Herrin JT, Black PH, Russell PS, Hirsch MS (1979): Controlled clinical trial of prophylactic human-leukocyte interferon in renal transplantation. Effects on cytomegalovirus and herpes simplex virus infections. New England Journal of Medicine 300:1345-1349.
6. Fox JC, Griffiths PD, Emery VC (1992): Quantification of human cytomegalovirus DNA using the polymerase chain reaction. Journal of Genetic Virology 73:2405-2408.
7. Fox JC, Kidd IM, Griffiths PD, Sweny P, Emery VC (1995): Longitudinal analysis of cytomegalovirus load in renal transplant recipients using a quantitative polymerase chain reaction: correlation with disease. Journal of Genetic Virology 76:309-319.
8. Goodrich JM, Mori M, Gleaves CA, DuMond C, Cays M, Ebeling DF, Buhles WC, DeArmond B, Meyers JD (1991): Early treatment with ganciclovir to prevent cytomegalovirus disease after allogenic bone marrow transplantation. New England Journal of Medicine 325:1601-1607.
9. Griffiths, PD (1995): In Zuckerman AJ, Bantavala JE, Pattison JR (eds): Cytomegalovirus "Principles and Practice of Clinical Virology," 3rd ed. Chichester: John Wiley & Sons Ltd, pp. 69-108.
10. Grundy JE, Lui SF, Super M, Sweny P, Moorhead J, Lui SF, Berry NJ, Fernando ON, Griffiths PD (1988): Symptomatic cytomegalovirus infection in seropositive kidney recipients: Reinfection with donor virus rather than reactivation of recipient virus. Lancet 2: 132-135.
11. Hirsch MS, Schooly RT, Cosimi AB, Russell PS, Delmonico FL, Tolkoff-Rubin NE, Herrin JT, Cantell K, Farrell ML, Rota TR, Rubin RH (1983): Effects of interferon-alpha on cytomegalovirus reactivation syndromes in renal-transplant recipients. New England Journal of Medicine 308:1489-1493.
12. Irragorri S, Pillay D, Serine M, Trompeter RS, Rees L, Griffiths PD (1993): Prospective cytomegalovirus surveillance in paedeatric renal transplant recipients. Peadeatric Nephrology 7:55-60.
13. Kidd IM, Fox JC, Pillay D, Charman H, Griffiths PD & Emery VC (1993): Routine application of the polymerase chain reaction for cytomegalovirus provides prognostic information in immunocompromised patients. Transplantation 56:867-871.
14. Kuhn JE, Wendland T, Schafer P, Mohring K, Wieland V, Elgas M, Eggers HJ (1994): Monitoring of renal allograft recipients by quantitation of human cytomegalovirus genomes in peripheral blood leukocytes. Journal of Medical Virology 44:398-405.
15. Lui SF, Ali AA, Grundy JE, Fernando ON, Griffiths PD, Sweny P (1992): Double-blind placebo-controlled trial of human lymphoblastoid interferon prophylaxis of cytomegalovirus infection in renal transplant recipients. Nephrology Dialogy Transplantation 7: 1230-1237.
16. Metselaar HJ, Rothbarth PH, Brouwer RM, Wenting GJ, Keekel J, Weimar W (1989): Prevention of cytomegalovirus-related death by passive immunisation. A double-blind placebo-controlled trial in kidney transplant recipients treated for rejection. Transplantation 48:264-266.
17. Pillay D, Ali AA, Lui SF, Kops E, Sweny P, Griffiths PD (1993): The prognostic significance of positive CMV cultures during surveillance of renal transplant recipients. Transplantation 56:103-108.
18. Plotkin SA, Starr SE, Freidman HM, Brayman K, Harris S, Jackson S, Tustin NB, Grossman R, Danfoe D, Barker C (1991): Effect of Towne live virus vaccine on cytomegalovirus disease after renal transplantation: A controlled trial. Annual International Medicine 114:525-531.
19. Ranjan D, Burke G, Esquenazi V, Milgrom M, Koleiat N, Roth D, Gomez C, Olson L, Babishkin S, Gharagozloo H, Miller J (1991): Factors affecting the ten-year outcome of human renal allografts: The effect of viral infections. Transplantation 51:113-117.
20. Rasmussen L, Morris S, Zipeto D, Fessell J, Wolitz R, Dowling A, Merigan TC (1995): Quantitation of human cytomegalovirus DNA from peripheral blood cells of human immunodeficiency virus-infected patients could predict cytomegalovirus retinitis. Journal of Infectious Diseases 171:177-182.
21. SAS Institute Incorporation (1989): "SAS/STAT Users' Guide, Version 6," 4th ed. Cevy, NC: SAS Inst. Inc.
22. Saltzman RL, Quirk MR, Jordan MC (1992): High levels of cytomegalovirus DNA reflect visceral organ disease in viremic immunosuppressed patients other than marrow recipients. Journal of Clinical Investigation 90:398-405.
23. Schafer P, Braun RW, Mohring K, Henco K, Kang J, Wendland T, Kuhn JE (1993): Quantitation of human cytomegalovirus target sequences in peripheral blood leukocytes by nested polymerase chain reaction and temperature gradient gel electrophoresis. Journal of General Virology 74:2699-2707.
24. Schmidt GM, Horak DA, Niland JC, Duncan SR, Forman SJ, Zaia JA (1991): A randomized controlled trial of prophylactic ganciclovir for cytomegalovirus pulmonary infection in recipients of allogenic bone marrow transplants. New England Journal of Medicine 324: 1005-1011.
25. Stagno S, Reynolds DW, Tsiantos A, Fuccillo DA, Long W, Alford CA (1975): Comparative serial virological and serological studies of symptomatic and subclinical congenitally and natally acquired cytomegalovirus infections. New England Journal of Medicine 300: 1345-1349.